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Purpose: To use a novel optical coherence tomography angiography (OCTA)
algorithm termed variable interscan time analysis (VISTA) to evaluate relative blood
flow speeds in polypoidal choroidal vasculopathy (PCV).
Methods: Prospective cross-sectional study enrolling patients with confirmed
diagnosis of PCV. OCTA of the retina and choroid was obtained with a prototype
swept-source OCT system. The acquired OCT volumes were centered on the
branching vascular network (BVN) and polyps as determined by indocyanine-green
angiography (ICGA). The relative blood flow speeds were characterized on VISTA-
OCTA.
Results: Seven eyes from seven patients were evaluated. Swept-source OCTA enabled
detailed enface visualization of the BVN and polyps in six eyes. VISTA-OCTA revealed
variable blood flow speeds in different PCV lesion components of the same eye, with
faster flow in the periphery of polyps and slower flow in the center of each polyp, as
well as relatively slow flow in BVN when compared with retinal vessels. BVNs
demonstrated relatively faster blood flow speeds in the larger trunk vessels and
relatively slower speeds in the smaller vessels.
Conclusions: Swept-source OCTA identifies polyps in most, but not all, PCV lesions.
This limitation that may be related to relatively slow blood flow within the polyp,
which may be below the OCTA’s sensitivity. VISTA-OCTA showed heterogeneous
blood flow speeds within the polyps, which may indicate turbulent flow in the polyps.
Translational Relevance: These results bring relevant insights into disease
mechanisms that can account for the variable course of PCV, and can be relevant
for diagnosis and management of patients with PCV.
Introduction
Polypoidal choroidal vasculopathy (PCV), an
entity first named by Yannuzzi et al.1 in 1990, is
characterized by a branching vascular network (BVN)
terminating in polypoidal lesions and is often
accompanied by serous or hemorrhagic retinal
pigment epithelium detachment (PED). While fluo-
rescein angiography remains the preferred imaging
modality for visualizing typical choroidal neovascu-
larization (CNV), it offers a limited documentation of
PCV lesions because these are located below the
retinal pigment epithelium (RPE). Indocyanine green
angiography (ICGA) is the current gold standard
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investigation for the diagnosis of PCV as it allows
better visualization of the choroidal vasculature.2
Both of these standard angiographic techniques are
invasive and involve the use of intravenous contrast
that can result in systemic adverse events and, rarely,
anaphylaxis.3–5
Optical coherence tomography (OCT) is a fast and
noninvasive imaging modality that plays an impor-
tant role in the diagnosis and clinical monitoring of
PCV lesions.6,7 Cross-sectional and enface structural
OCT suggest the presence of PCV lesions through
typical findings such as multiple or multilobulated
PEDs, sharp PED peaks, and PED notching,8 as well
as rounded hyporeflective structures correspondent to
the polyp lumen. These areas are often seen within the
hyperreflective lesions and are adherent to the
underside of the RPE. A BVN can also be visualized
as a double-layered structure with high reflectivity
immediately below the RPE.9 Despite these charac-
teristic features, it is not always possible to accurately
delineate the complete extent of the PCV lesion with
structural cross-sectional OCT scans alone, and
structural enface OCT is superior in this regard.10
OCT angiography (OCTA) is a new OCT-based
technology that allows for volumetric and depth-
resolved imaging of the retinal and choroidal vascu-
latures without the need for invasive dyes, by using
blood cells as motion contrast.11,12 OCTA has
enjoyed widespread usage in patients with CNV
because it allows for visualization of the neovascular
complex both above and beneath the RPE without
the use of intravenous dye.11,13–19 There are previous
studies showing that the BVN in PCV lesions can be
reliably detected using OCTA.20–24 However, there
have been varying reports on the limited sensitivity of
OCTA in detecting polyps compared with ICGA.20–24
It has been hypothesized that slow blood flow in this
neovascular complex may be below the sensitivity
threshold of OCTA systems to detect blood flow, but
this has not yet been confirmed nor demonstrated.24
In addition to limited flow sensitivities, current
commercial OCTA systems primarily report informa-
tion pertaining to the presence or absence of blood
flow—having velocities within a range defined by the
interscan time, which is typically close to 5 ms—but
provide little-to-no direct information about flow
speeds. This is an unfortunate shortcoming, as
knowledge of blood flow speeds may provide further
insight into PCV pathophysiology. Recently, an
OCTA-based algorithm, termed variable interscan
time analysis (VISTA), has been developed by our
group for detecting and displaying relative blood flow
speeds in the retinal and choroidal vasculatures.25,26
The aim of the present study is to use high-speed
swept-source OCT technology in conjunction with
VISTA-OCTA to analyze relative blood flow speeds
in PCV lesions.
Methods
This was a cross-sectional, observational study
conducted at the New England Eye Center of Tufts
Medical Center (Boston, MA) and approved by the
Tufts Medical Center and Massachusetts Institute of
Technology (Cambridge, MA) institutional review
boards. The research adhered to the tenets of the
Declaration of Helsinki and complied with the Health
Insurance Portability and Accountability Act of 1996.
Written informed consent was obtained before swept-
source OCT imaging.
Patient Selection
Patients with PCV were seen at the New England
Eye Center between August 2015 and January 2016
and prospectively recruited to be imaged on swept-
source OCT. Patients were submitted to comprehen-
sive ophthalmologic examination, and the diagnosis
of PCV was confirmed by ICGA.
Image Acquisition and Analysis
A high-speed swept-source OCT prototype system,
developed at the Massachusetts Institute of Technol-
ogy, was used in this study. The system uses a vertical
cavity surface emitting laser operating at approximate-
ly 1050-nm wavelength and 400,000-kHz A-scan rate.
For each OCT volume, a total of five repeated B-scans
from 500 sequentially, uniformly spaced, slow-scan
locations were acquired, with each B-scan consisting of
500 A-scans. The interscan time, accounting for the
mirror scanning duty cycle, is approximately 1.5 ms,
with the total acquisition time being approximately 3.8
seconds. The axial and transverse resolutions are
approximately 8 to 9 lm and approximately 20 lm
(full-width-at-half-maximum) in tissue, respectively.
For both 3 3 3 mm and 6 3 6 mm, the acquired
OCT volumes were centered on the area containing the
BVN and polyps, as seen on ICGA. Patients were
asked to fixate on an internal target during OCT
acquisition. Motion correction was performed using
registration of two orthogonally acquired volumes,
which are merged into a single volume.27,28
A custom Cþþ application was used for image
processing, and ImageJ software (http://imagej.nih.
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gov/ij/; provided in the public domain by the National
Institutes of Health, Bethesda, MD) was used for
visualization. A flat segmentation line was manually
adjusted using the orthogonal view, and structural en-
face and OCTA images were formed by projecting the
OCT data through the depths spanned by the lesion.
VISTA-OCTA was performed as previously de-
scribed.25,26 In brief, VISTA-OCTA images were
formed as follows. First, OCTA images correspond-
ing to 1.5-ms interscan times were formed by
comparing temporally adjacent repeated OCT cross-
sectional scans; OCTA images correspond to 3-ms
interscan times were formed by comparing every
other repeated OCT cross-sectional scan. Second, 1.5-
and 3-ms interscan time OCTA volumes were
projected through the depths spanned by the PCV
lesion, thereby yielding 1.5- and 3-ms enface OCTA
images. A filtered ratio of these enface images was
computed and mapped to a color-coded display. In
our VISTA color-coded convention, red indicates
relatively fast blood flow speeds and blue indicates
relatively slow blood flow speeds.
Two independent readers (EAN and DF) of the
Boston Image Reading Center analyzed the 33 3-mm
and 6 3 6-mm enface structural (OCT) and flow
(OCTA) images to determine PCV features (e.g.,
identification of polyps and branching vascular
network). VISTA-OCTA images were qualitatively
analyzed for blood flow speed information. Disagree-
ment between the two observers was resolved by open
adjudication.
Results
Seven eyes from seven patients (5 Asian; 2 African
American) were enrolled in this study. The mean age
6 standard deviation of the studied population was
71 6 10.2 years. Five patients (71%) were women and
two (29%) were men. One patient had a history of
enucleation of the contralateral eye because of
massive hemorrhage. All subjects had a history of
one intravitreal injection of anti–vascular endothelial
growth factor in the study eye to manage exudative
manifestations of PCV, prior to enrollment in the
study.
ICGA identified the presence of BVN, polyps and
dilated choroidal vessels in all study eyes. The mean
time of identification through vascular filling of BVN
and polyp on video ICGA were 25.2 6 5.9 and 23 6
4.5 seconds.
Swept-source OCTA enabled detailed enface visu-
alization of the BVN in six of seven study eyes
(85.7%); visualization of polyps was also possible in
six of seven study eyes (85.7%). Corresponding cross-
sectional structural OCT scans helped identify the
depth and location of the polyps relative to the RPE
in all seven study eyes (100%).
VISTA-OCTA provided information about rela-
tive blood flow speeds in all OCTA images in which
the BVN and/or polyps were visible. Blood flow speed
within polyps varied from polyp-to-polyp within the
same eye, as well as from patient-to-patient. Some
polyps demonstrated relatively faster flow speeds
(red-yellow color-coded velocity range; Fig. 1) while
others demonstrated slower flow speeds (blue-green
color-coded velocity range; Figs. 2, 3). A common
finding was that VISTA-OCTA–derived relative
blood flow speeds within a single polyp were not
uniform; there was a range of blood flow speeds
within a single polyp (Fig. 4). Based on VISTA-
OCTA, blood flow in some polyps appeared slower at
the center of the polyp, and faster close to the lesion
walls (Fig. 1). In all documented eyes, BVNs have
Figure 1. PCV on VISTA-OCTA. Variable blood flow speeds in
polyps from the same neovascular complex. Left eye of an 84-year-
old woman with PCV. (A) ICGA aligned to the same area as the
OCTA and VISTA-OCTA images, demonstrates bright spots
corresponding to two polyps (yellow and white arrows) and a
BVN (white dashed line). (B) OCTA shows both polyps and the BVN
in the same projection. (C) VISTA-OCTA demonstrates variable
relative blood flow speeds in two polyps in the same eye. The
yellow arrow shows a polyp with relatively fast blood flow speed
(represented by red color–coded OCTA), while the white arrow
shows a polyp with relatively slow blood flow speed (represented
by green- and blue color–coded OCTA). (D, E) The structural cross-
sectional scan and OCTA cross-sectional scan, respectively, taken
through the white line as seen in (A). The yellow arrow points to a
polyp. Note that localized decorrelation signal within the polyp in
the OCTA cross-sectional scan. (F) Structural enface OCT image
shows a polyp and the BVN.
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relatively slow flow in comparison to blood flow
speed of retinal vessels. Variable blood flow speed was
also observed in BVNs, with relatively faster blood
flow speeds in the larger trunk vessels and relatively
slower speeds in the smaller vessels (Figs. 5, 6).
Discussion
PCV lesions are characterized by polypoidal
terminations connected to a BVN.1,2,29–31 It is still a
matter of debate if PCV is a variant of CNV
secondary to age-related macular degeneration, or if
this is a distinct entity. It has been hypothesized that
polypoidal lesions in the vascular terminations occur
because of a localized delay in choroidal capillary
lobular filling, which causes capillary and venous
congestion in the affected lobules. This would impact
the RPE–Bruch’s membrane complex and produce a
PED.32 The natural history of PCV is widely variable,
as well as its response to treatment including anti–
vascular endothelial growth factor agents or photo-
dynamic therapy. Large serosanguinous PEDs typi-
cally occur in eyes with PCV, and the polyps
commonly bleed between the RPE and Bruch’s
membrane. Intriguingly, self-resolution may also be
observed in the natural course of polypoidal le-
sions.30,33
The current gold standard for diagnosing PCV is
ICGA, an invasive test with potential risks for the
patient.2,5 OCTA is a noninvasive imaging technology
that can separately visualize the retinal and choroidal
vasculatures. This technology is increasingly being
used to image CNV because it can visualize the
neovascular complex both above and beneath the
RPE.11,13–19 However, in recent studies the detection
rate of polyps on OCTA compared with ICGA has
varied widely, ranging from 45% to 92% detec-
tion.20–22 Interestingly, Tanaka et al.34 found that
OCTA best detected polyps that were observed to be
pulsating on video ICGA. In the current study, the
polyp detection rate was in the upper range of
previously published studies. The longer wavelengths
used in the prototype swept-source OCT device might
favor the detection of polyps and other choroidal
vascular structures, located deeper in the fundus
tissue. Such advantage has been previously demon-
strated in documenting typical choroidal neovascu-
Figure 2. PCV on VISTA-OCTA. Variable blood flow speed within
polyp and BVN. Left eye of a 71-year-old man with PCV. (A) Early
phase ICGA identifies two polyps and the BVN. Polyps appear as
bright spots (white and yellow arrows). The BVN is demarcated by a
dashed white line. (B, E) OCTA images of the same eye, but with
different projections in order to capture different aspects of the
lesion, which occur at different depths of the tissue. (B) Clearly
shows both polyps while (E) shows the BVN. (C) VISTA-OCTA image
showing relatively slow blood flow speed within the polyps,
represented by blue color–coded OCTA in both polyps (white and
yellow arrows). (F) A mixture of relatively fast and slow blood flow
speeds in the BVN, represented by a range of colors. (D) A
structural cross-sectional scan showing a polyp corresponding to
the white line in (A) and yellow arrow in (A–C).
Figure 3. PCV on VISTA-OCTA. Relatively slow flow within the
polyp. Left eye of a 62-year-old woman with PCV. (A) ICGA, aligned
to the same area as the OCTA and VISTA-OCTA images,
demonstrates bright spot corresponding to a polyp (white
arrow). (B) OCTA shows the polyp (white arrow). (C) VISTA-OCTA
demonstrates a relatively slow flow (green- and blue–color coded)
within the polyp (white arrow). Note the black gaps in (B, C) are
caused by motion image artifact due to the merging of OCT/OCTA
scans in the x and y axis. (D, E) The structural cross-sectional OCT
and OCTA scans, respectively, taken through the white line
indicated in (A). The white arrow points to a polyp. Note the
localized decorrelation signal within the polyp in the OCTA cross-
sectional scan. (F) Structural enface OCT image shows a polyp as a
round hyporeflective area (white arrow), surrounded by
multilobulated pigment epithelium detachment.
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larization and choroicapillaris.19,35–37 While the
swept-source OCT technology might contribute to
improved rate of polyp detection, the VISTA
algorithm on the other hand, does not add to this
greater sensitivity. This is because the interscan times
used in this study (1.5 and 3 ms) are shorter than
those commonly used in standard commercial OCT
systems (~5 ms). Thus, all else being equal, the
slowest detectable flow using a commercial system
should actually be relatively lower than that of our
prototype system.
It is important to note that, among the recent
literature, the definition of positive identification of
polyps on OCTA is a matter of controversy. Some
authors consider positive detection of polyps on
OCTA as seeing an OCTA decorrelation signal.38
Other authors have described polyps on OCTA as
hyperflow round structure surrounded by hypoflow
halo or simply a hypoflow round structure at the level
of the choriocapillaris.21,24 It has been hypothesized
that turbulent blood flow within polyps might
underlie this variability.20,21,24,38
In this study, a prototype high-speed swept-source
OCT device was used in conjunction with the VISTA
algorithm to visualize variations in relative blood flow
speeds within polypoidal lesions. Our data suggests a
range of relative blood flow speeds within the polyps
and the BVN. This was demonstrated between
different components of the lesion in the same eye,
and between different eyes. While the mechanism of
this variable flow speed is not yet clear, we believe
that the relative blood flow speed information
provided by VISTA algorithm may inform on the
diagnosis of PCV based on OCTA, and may help to
elucidate the pathophysiology of PCV. In particular,
some polyps appeared to have faster blood flow in the
periphery and slower blood flow in the center, which
might indicate turbulence within the polyps and might
be related to the self-obliteration process occasionally
observed in the natural course of the disease. With
respect to blood flow speeds within BVNs, our results
showed relative faster flow in the larger trunk vessels
and slower flow speeds in the smaller vessels. Similar
findings have been recently shown in CNV and retinal
neovascularization in proliferative diabetic retinopa-
thy using VISTA-OCTA.26,39 Once treatment para-
Figure 5. PCV on VISTA-OCTA. Heterogeneous blood flow speed
within the BVN. Right eye of a 62-year-old woman with polypoidal
choroidal vasculopathy (PCV). (A) ICGA and (B) OCTA identifying
two polyps (yellow and white arrows) and BVN (white dotted lines).
(C) VISTA-OCTA image shows relatively slow flow within the polyps
(green color–coded OCTA). A mixture of blood flow speeds within
BVN can be seen, but slightly faster flow within a main trunk vessel
(white asterisk) and relatively slow blood flow speeds at the
periphery of the BVN. (D, E) Structural OCT and OCTA cross-
sectional scans, respectively, corresponding to the white line in (A).
(F) The structural enface OCT allows for visualization of the BVN
(white dotted line) and the polyps (yellow and white arrows).
Figure 4. PCV on VISTA-OCTA. Heterogeneous blood flow speed
within the polyp. Left eye of a 61-year-old woman with polypoidal
choroidal vasculopathy (PCV). (A) ICGA showing the BVN and
polypoidal lesion. (D) Larger scale of the macular area documented
by ICGA in (A) (white dashed line), with the BVN (white dotted line)
and a polyp with bright periphery toward the polyp wall and dark
center (white arrow). (B, C, E, F) OCTA images of the same eye, but
projected through different axial depths (different segmentation
levels) capturing different components of the lesion. (B, C) Clearly
shows the polyp with blood flow toward the polyp wall, but not in
the center. (E, F) Clearly shows the BVN. The dark circle in this
segmentation level is caused by blockage artifact in the
topography of the polyp, more evident toward the polyp wall
(C, F) are OCTA scans applying VISTA-OCTA. (C) Shows relatively
slow blood flow speed within the polyp, represented by green- and
blue color–coded OCTA. (F) Shows relatively fast blood flow speed
in the BVN, represented by mostly red color-coded OCTA.
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digms are properly established on these new technol-
ogies, quantitative assessments of lesion flow may
potentially contribute to patient management, in-
forming on lesion activity and potentially indicating
response to therapeutic interventions.
Limitations of this study include a relatively small
sample size, but the consistency of our observations
indicates high reproducibility of the results. The fact
that all patients were previously treated with one
intravitreal injection of anti–vascular endothelial
growth factor raises the question whether naı¨ve-
treatment PCV lesions will show similar blood flow
patterns, and naı¨ve-treatment lesions should be
investigated through the same method in a future
study. In addition, we did not establish a direct
comparison between ICGA filling speed and VISTA-
OCTA–relative flow, as this was not within the scope
of this work. There are also limitations with regard to
the data processing that preclude a broader use of the
strategy employed in this study: the custom software
used to process the swept-source OCT data in the
present study does not have automated segmentation,
and therefore manual adjustment of enface projection
boundaries was required to achieve the best quality
image, which is time consuming and requires trained
assessors. Additionally, in its current form, the
VISTA-OCTA algorithm only provides information
about relative blood flow speeds (e.g., ‘‘the flow in
vessel A is faster than that in vessel B’’), but not about
absolute blood flow speeds (i.e., ‘‘the flow in vessel A
is 3 mm/s, and that is vessel B is 2 mm/s). Future
development of the VISTA algorithm to allow for
quantitative measurements of absolute blood flow
speed is an important step to enabling further
investigation into blood flow speeds in PCV and
other clinical presentations of CNV. Finally, there are
some factors that might confound the interpretation
of VISTA-OCTA. In particular, VISTA-OCTA sig-
nals are derived from OCTA signals, which are in turn
derived from repeated OCT scans. Thus, artifacts in
either the OCT or OCTA imaging can degrade the
VISTA-OCTA signal. For example, low OCT signals
generates noisy OCTA images, which in turn generate
noisy VISTA-OCTA images; similarly, errors in
projection ranges, patient motion artifacts, poor
optical focusing, and other factors known to corrupt
OCTA signal may also corrupt the VISTA-OCTA
images.40 While we have taken measures to reduce the
likelihood of such errors, for example, by inspecting
coregistered OCT and OCTA data in an orthoplane
manner, manually selecting projection ranges, and
using a longer wavelength swept-source OCT system
that has reduced attenuation artifacts, we have not yet
performed formal repeatability analyses of the VIS-
TA-OCTA, particularly in the context of PCV. It is
therefore possible that additional imaging artifacts
are also present in our dataset.
In conclusion, even though ICGA remains the gold
standard for diagnosing PCV, it is invasive and lacks
depth resolution.2,32,41 OCTA is a noninvasive and
fast technique for three-dimensional and depth-
resolved fundus imaging, allowing different vascular
layers of the retina and choroid to be independently
documented. Previous studies have had mixed success
in identifying polypoidal lesions on OCTA, and, as in
our study, found that OCTA was not able to visualize
lesions in all cases. VISTA-OCTA, a recently
proposed OCTA enhancement that enables visualiza-
tion of relative blood flow speeds, shows slow and
variable blood flow speed in polypoidal lesions, and
may increase our understanding of PCV pathophys-
iology.
Figure 6. PCV on VISTA-OCTA. Increased blood flow speed within
the BVN trunk vessel. Left eye of a 71-year-old man with PCV. (A)
ICGA identifies both the BVN trunk vessel (white dotted line) and
the polyp (white arrow), located at different sites. (B) OCTA shows
the trunk vessel in the BVN complex (within the white dotted lines).
No decorrelation signal from the polyp is shown in this OCTA slab.
(C) VISTA-OCTA image shows variable blood flow speeds within
BVN complex, with faster flow within a main trunk vessel (white
dotted line) and larger vessels forming a peripheral arcade, and
relatively fast-to-moderate blood flow speeds in smaller vessels
toward the center of the BVN. (D) Structural cross-sectional OCT
corresponding to the white line indicated in (A) shows a circular
hyporeflective area corresponding to a polyp (arrow). (E) Cross-
sectional OCTA scan of the same region of (E) shows a low
decorrelation signal from the polyp lesion. (F) The structural enface
OCT allows visualization of the BVN trunk vessel (white dotted line)
surrounded by a hyperreflective border that delineates the
extension of the neovascular complex within a multilobulated
pigment epithelium detachment.
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